Michael Thompson is a Professor of Bioanalytical Chemistry with the University of Toronto. He has held a number of distinguished research posts, including the Leverhulme Fellowship at Durham University and the Science Foundation Ireland E. T. S. Walton Research Fellowship at the Tyndall National Institute, Cork City. He was made a Fellow of the Royal Society of Canada in 1999. He has been awarded many prestigious international prizes for his research, including the Robert Boyle Gold Medal of the Royal Society of Chemistry, the E. W. R. Steacie Award of the Chemical Society of Canada, the Theophilus Redwood Award of the Royal Society of Chemistry, and the Fisher Scientific Award in Analytical Chemistry of the Chemical Society of Canada. He has served on the Editorial Boards for a number of major international journals, including Analytical Chemistry, Analyst, Talanta, Analytica Chimica Acta, Biosensors and Bioelectronics, and Journal of Breast Cancer Research and Advancements. And He is the Editor-in-Chief of the monograph series Detection Science for the Royal Society of Chemistry, U.K. He is also the member of UK Royal Society of Chemistry, International Society for Electrochemistry, Canadian Institute for Neutron Scattering, American Chemical Society, and IEEE.

Daniel Falush, PhD in Biology, is a researcher at the Shanghai Institute of Immunology and Infection, Chinese Academy of Sciences. He received his BA (Hons) from the University of Cambridge in 1992 and his PhD from University College London in 1998. He has held senior research positions at Kyushu University in Japan, the Max Planck Institute for Evolutionary Anthropology in Germany, the University of Oxford, the University of Tokyo, and the University of Bath in the UK. He has published over 80 papers in top journals such as Nature, Science, ISME, Elife, and Nature Communications, with over 30,000 citations and an h-index of 60. He has led numerous research projects, including key R&D projects of the Ministry of Science and Technology of China, the National Natural Science Foundation of China, the China National Senior Foreign Experts Program, Wellcome Trust Project Grants, and the Science Foundation of Ireland. In 2021, he was selected as one of the top 10 Chinese scholars in biology in Elsevier's "Top Global Scientists Ranking." He developed software such as Linkage model of STRUCTURE, STRUCTURE 2.2, fineSTRUCTURE, ClonalFrame, GlobeTrotter, Badmixture, ClonalOrigin, and FineRADstructure, which have been recognized in the industry and widely cited.

William C. Cho is Senior Researcher at Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. He is a Chartered Scientist granted by the Science Council (UK) and a fellow member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science, and Hong Kong Society for Molecular Diagnostic Sciences. Besides, he is also a registered Chinese medicine practitioner. Dr Cho has published more than 600 peer-reviewed papers on international academic journal papers and dozens of books covering cancer biomarkers, proteomics, and microRNAs. He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan), etc. And he was recognized as a Highly Cited Researcher in 2023 by Clarivate.

Dr. Christopher L. Antos obtained his B.S. Degrees from Indiana University in Bloomington in 1993. He then went to Freiburg, Germany on a Fulbright Scholarship and worked in the Laboratory of Dr. Rolf Kemler at the Max-Planck Institute for Immunology. In 1996, Dr. Antos started his Ph.D. work in the laboratory of Dr. Eric Olson at UT Southwestern Medical Center at Dallas. After finishing his Ph.D., he then completed his post-doctoral training in the laboratory of Dr. Christiane Nüsslein-Volhard at the Max-Planck Institute for Developmental Biology in Tübingen, Germany from 2003-2007. In 2008, Dr. Antos established his own laboratory as faculty at the DFG-Center for Regenerative Therapies Dresden of the Technische Universität Dresden. Dr. Antos joined ShanghaiTech University as an Associate Professor in Dec. 2016. Dr. Christopher has published dozends of research paper in many international academic journals.

Dipayan Rudra graduate from Albert Einstein College of Medicine with the doctor degree in 2005. Then he has been worked as Postdoctoral Fellow in University of Washington from 2006-2008, Research Fellow in Memorial Sloan Kettering Cancer Centre from 2009-2013, Principal Investigator in Academy of Immunology and Microbiology, Institute for Basic Science from 2013-2019, Research Associate Professor in Integrative Biosciences and Biotechnology (IBB), Pohang University of Science and Technology from 2019-2020, and Senior Scientist in Immunobiome Inc. from 2020-2021. Now he is the Associate Professor, Researcher, and Doctoral Supervisor in School of Life Science and Technology, ShanghaiTech University. His researches mostly focus on immune tolerance, autoimmunity and inflammation, regulatory T cells, and tumor Immunology. And he also published dozens of papers on international academic journals, and been the reviewer of many internation outstanding journals. He is the Editorial Member of Scientific Reports, and been the Guest Editor of International Reviews of Immunology.

Dr. Liang is a tenure-track assistant professor of Medicine, and his research focuses on the applications of CRISPR-mediated genome editing for gene therapy and cancer research. As a graduate student at University of Bern (Switzerland), he investigated drug resistance mechanisms in lung cancer with FGFR1 amplification and KRAS mutation using CRISPR-based knockout screens. This experience provided him with a deep understanding of how CRISPR technology can be leveraged to elucidate drug resistant mechanisms. During his postdoc training at UMASS medical school, he developed an improved prime editor (PE) capable of generating orthotopic liver cancer models and correcting E342K mutations in PiZ mice. To address safety concerns, he developed two technologies: GUIDE-tag (for SpCas9) and PE-tag (for PE). These tools enable genome-wide profiling of off-target sites in mammalian cell lines and adult mouse liver. In addition, he developed and validated a dual adeno-associated virus (AAV) CRISPR platform capable of effective editing in the mouse lung. To reduce immune responses and enable repeated dosing, he identified inhalable delivery lipids for Cas9 mRNA and sgRNA. These lipid nanoparticles efficiently mediate gene editing in lung epithelium. Dr. Liang is the Member of Masonic Cancer Center, American Association for the Study of Liver Diseases (AASLD), Center for Genome Engineering (CGE), American Association for Cancer Research (AACR), and American Society of Gene and Cell Therapy (ASGCT).